Bevacizumab in the treatment of metastatic colorectal cancer

Francesco Caprioni, Giuseppe Fornarini

Research output: Contribution to journalArticlepeer-review


Anglogenesis is essential for tumor growth and metastasis, and has become a useful target for novel biological agents. Vascular endothellal growth factor (VEGF) is one of the most important anglogenesis regulators. Bevacizumab is a recombinant humanized anti-VEGF monocional antibody recently approved in Europe and the USA for first- and second-line therapy (in combination with chemotherapy) for metastatic colorectal cancer. It has a proven impact on survival, as demonstrated in large Phase III clinical trials. Treatment with bevacizumab is generally well tolerated, with hypertension and arterial thromboembolic events being the main side effects. Currently, its role in the adjuvant setting, In combination with chemotherapy, is being evaluated in large Phase III clinical trials.

Original languageEnglish
Pages (from-to)141-148
Number of pages8
JournalFuture Oncology
Issue number2
Publication statusPublished - Apr 2007


  • Angiogenesis
  • Bevacizumab
  • Chemotherapy
  • Colorectal carcinoma
  • Survival

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Fingerprint Dive into the research topics of 'Bevacizumab in the treatment of metastatic colorectal cancer'. Together they form a unique fingerprint.

Cite this